Abstracts Archive - Page 2296 of 2607 - ACR Meeting Abstracts

Abstract Number: 2057 • 2013 ACR/ARHP Annual Meeting
Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Ann M. Reed¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla³, Helen Khun², Rohit Aggarwal⁴, Dana P. Ascherman⁵, Marc C. Levesque⁶ and Chester V. Oddis⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The aim of this study was to examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as biomarkers of…
Abstract Number: 2058 • 2013 ACR/ARHP Annual Meeting
Evidence For Immunotherapy In Polymyositis and Dermatomyositis: A Systematic Review
Erin Vermaak¹ and Neil J McHugh^1,2, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare chronic inflammatory disorders of muscle. The morbidity and mortality associated with these conditions remains significant despite treatment,…
Abstract Number: 2059 • 2013 ACR/ARHP Annual Meeting
Mortality In Polymyositis and Dermatomyositis: A Single Centre Study
Erin Vermaak¹, Gavin Shaddick² and Neil J McHugh^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: PM and DM are rare chronic inflammatory disorders of muscle, and data on long-term prognosis and outcomes are lacking. Previous studies have reported 5-year…
Abstract Number: 2060 • 2013 ACR/ARHP Annual Meeting
Influence Of Anti-Ro/SSA Autoantibodies On Cinical Characteristic Of a Cohort Of Myositis Patients
Simone Barsotti¹, Rossella Neri², Valentina Iacopetti³, Chiara Baldini², Nicoletta Luciano², Antonio Tavoni⁴, Anna d'Ascanio⁵ and Stefano Bombardieri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Internal medicine, Barga, Italy, ⁴University of Pisa, Immunoallergology Unit, Pisa, Italy, ⁵Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy, ⁶Rheumatology Unit, Pisa, Italy
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of acquired diseases, characterized by immunoflogistic processes primarily involving the skeletal muscle. Myositis-associated antibodies are frequently detected…
Abstract Number: 2061 • 2013 ACR/ARHP Annual Meeting
Good Inter-Rater Reliability Of Myositis Experts In Assessing Clinical Improvement
Rohit Aggarwal¹, Nicolino. Ruperto², Brian Erman³, Saad Feroz⁴, Jiri Vencovsky⁵, Adam Huber⁶, Sheila K. Oliveira⁷, Angela Pistorio⁸, Clarissa Pilkington⁹, Angelo Ravelli¹⁰, Brian M. Feldman¹¹, Howard Rockette¹², Frederick W. Miller⁴, Peter A. Lachenbruch⁴ and Lisa G. Rider⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Istituto Gaslini-PRINTO, Genoa, Italy, ³National Institute of Health, Bethesda, DC, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸PRINTO, Genoa, Italy, ⁹Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹⁰Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ¹¹Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs) for adult or juvenile dermatomyositis (DM) and polymyositis (PM).…
Abstract Number: 2062 • 2013 ACR/ARHP Annual Meeting
Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo-1 Autoantibody
Rohit Aggarwal¹, Diane Koontz², Zengbiao Qi³ and Chester V. Oddis⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The clinical characteristics of dermatomyositis (DM) patients possessing the anti-Jo-1 autoantibody (autoAb) are not well known. We analyzed the clinical features and prognosis of…
Abstract Number: 2063 • 2013 ACR/ARHP Annual Meeting
Identification Of Autoantibodies To Tyrosyl–Transfer RNA Synthetase Associated With Anti-Synthetase Syndrome
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Koji Tahara², Kaori Ito², Hiroaki Hattori², Takahisa Gono¹, Kae Takagi¹, Masanori Hanaoka¹, Yuko Ota¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Advanced Medical Technology and Development, BML, Saitama, Japan
Background/Purpose : Autoantibodies directed against the aminoacyl transfer RNA (tRNA) synthetases are associated with myositis, arthritis, Raynaud’s phenomenon, mechanic’s hands, fever, and interstitial lung disease,…
Abstract Number: 2064 • 2013 ACR/ARHP Annual Meeting
An Autoimmune Myositis-Overlap Syndrome Associated With Autoantibodies To Nuclear Pore Complexes ‒ Description and Long-Term Follow-Up Of The Anti-Nup Syndrome
Catherine Isabelle¹, Marie-Christine Dabauvalle², Marvin J. Fritzler³, Ira N. Targoff⁴, Rose Goldstein⁵, Yves Troyanov¹, Michel Gagné¹, Jean-Pierre Raynauld¹ and Jean-Luc Senécal¹, ¹Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²University of Würzburg, Würzburg, Germany, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis encompasses various myositis-overlap syndromes, each one being identified by the presence of serum marker autoantibodies. We describe a novel myositis-overlap syndrome in…
Abstract Number: 2065 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies
Xin Lu¹, Guochun Wang², Qinglin Peng³, Kai Yuan⁴ and Hanbo Yang⁵, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, Beijing, China, ²Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ³Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, ⁴Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ⁵Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM). Methods: Sera from 198 Chinese…
Abstract Number: 2066 • 2013 ACR/ARHP Annual Meeting
Distinct Arthropaties In Patients With Anti-Aminoacyl tRNA Synthetase Antibodies: Utility Of Autoantibody Profiles In Discrimination
Yuko Kaneko¹, Hironari Hanaoka¹, Michito Hirakata², Tsutomu Takeuchi¹ and Masataka Kuwana¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Medical Education Center, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Arthritis is observed frequently in patients with anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies and is usually not destructive like rheumatoid arthritis (RA). Despite several…
Abstract Number: 2067 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Associated With Inflammatory Myopathy and Other Systemic Autoimmune Rheumatic Diseases In Sera From Breast Cancer Patients
Monica Vázquez-Del Mercado¹, Adrian Daneri-Navarro², Beatriz Teresita Martín-Márquez³, Raul Vargas Ramirez⁴, Diego Velasco-Sanchez⁵, Jason Y.F. Chan⁶, S. John Calise⁷, Edward K.L. Chan⁷ and Minoru Satoh⁶, ¹Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Hospital Civil JIM, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, ²Laboratorio de Inmunología, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, ³Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Guadalajara, Mexico, ⁴CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, ⁵1. Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, ⁶Medicine, University of Florida, Gainesville, FL, ⁷Oral Biology, University of Florida, Gainesville, FL
Background/Purpose: Various autoantibodies have been reported in cancer patients, however, results are inconsistent. In dermatomyositis (DM), striking association between autoantibodies to p155/140 (transcription intermediary factor…
Abstract Number: 2068 • 2013 ACR/ARHP Annual Meeting
Comparison Of Radioimmunoprecipitation Versus Antigen Specific Assays For Identification Of Myositis Specific Autoantibodies In Dermatomyositis Patients
Eun Ha Kang¹, Eun Young Lee², Yun Jong Lee³, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ⁴Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: To confirm the antigen specificities of autoantibodies that precipitate 140 kDa (anti-p140) or 155/140 kDa polypeptides (anti-p155/140) on radioimmunoprecipitation (RIP) in Korean patients with…
Abstract Number: 2029 • 2013 ACR/ARHP Annual Meeting
Exposure-Response Modeling Of Canakinumab In The Avoidance Of Flares In Children With Systemic Juvenile Idiopathic Arthritis
Yuan Xiong¹, Wenping Wang¹, William Ebling¹, Haiying Sun¹, Olivier Luttringer², Ken Abrams¹, Nicola Ruperto³ and Hermine Brunner⁴, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Istituto Gaslini, Genova, Italy, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Canakinumab (CAN), a fully human selective anti-IL-1β monoclonal antibody, has been shown to be efficacious in systemic juvenile idiopathic arthritis (SJIA), resulting in significantly…
Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Sarah Thomas¹, Nabeel Borazan², Lewei Duan³, Nashla Barroso⁴, Sara Taroumian⁵, Banjamin Kretzmann⁶, Ricardo Bardales⁶ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, Rheumatology UCLA, Los Angeles, CA, ³David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁵Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ⁶Rheumatology, University of California Los Angeles, los angeles, CA

AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
Abstract Number: 2031 • 2013 ACR/ARHP Annual Meeting
GRAID – Interim Analysis Of The Retrospective German Register In Autoimmune Diseases
Thomas Dörner¹, Enno Schmidt², Christoph Fiehn³, Frank Behrens⁴, Rebecca Fischer-Betz⁵, Martin Fleck⁶, Julia Holle⁷, Joerg C. Henes⁸, Annett M. Jacobi⁹, Christian Kneitz¹⁰, Esther Wittenborn¹¹, Fabian Proft¹², Hendrik Schulze-Koops¹³ and Christof Iking-Konert¹⁴, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, University of Lübeck, Lübeck, Germany, ³ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ⁴CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ⁵Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany, ⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ⁷Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ⁹Rheumatology Internal Medicine D, University Hospital Münster, Münster, Germany, ¹⁰Internal Medicine II, Hospital Südstadt, Rostock, Germany, ¹¹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹²Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ¹³Division of Rheumatology, University of Munich, Munich, Germany, ¹⁴Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: Autoimmune diseases are characterized by high morbidity and lead frequently to physical disability and loss of income. They are the third most important disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].